Group T3: Therapeutic Nuclear Medicine
9 items with their schedule fees and Medicare benefits.
| Item | Fee | 75% | Out of hospital |
|---|---|---|---|
| 16003Intra-cavitary administration of therapeutic Yttrium 90 into a body cavity for treatment purposes, excluding preliminary procedures and selective internal radiation therapy cases. | $1,698.50 | $1,273.90 | $1,594.00 (85%) |
| 16006Administration of radioactive iodine-131 as a single therapeutic dose to treat thyroid cancer. | $1,144.95 | $858.75 | $1,040.45 (85%) |
| 16009Administration of a single therapeutic dose of Iodine 131 to treat thyrotoxicosis. | $554.65 | $416.00 | $471.50 (85%) |
| 16012IV administration of radioactive phosphorus-32 for therapeutic treatment of conditions such as polycythemia vera or essential thrombocythemia. | $3,185.75 | $2,389.35 | $3,081.25 (85%) |
| 16015Administration of Strontium 89 injection for bone pain relief in patients with skeletal metastases when systemic chemotherapy is unavailable or ineffective and conventional radiotherapy is inadequate or unsuitable due to widespread bone pain sites. | $4,890.05 | $3,667.55 | $4,785.55 (85%) |
| 16018Injection of Samarium-153 to relieve bone pain from skeletal metastases when systemic chemotherapy is unavailable or ineffective, and conventional radiotherapy is inadequate or unsuitable due to widespread pain sites. | $5,261.65 | $3,946.25 | $5,157.15 (85%) |
| 16050Administration of Lutetium 177 PSMA for metastatic castrate-resistant prostate cancer in PSMA-positive patients who have progressed after taxane and androgen receptor inhibitor treatment, with imaging; maximum 2 cycles. | $8,208.00 | $6,156.00 | $8,103.50 (85%) |
| 16055Administration of Lutetium 177 PSMA with whole body imaging within 36 hours for metastatic castrate-resistant prostate cancer, once per cycle, maximum 4 cycles, following prior imaging assessment and without intervening disease progression. | $8,208.00 | $6,156.00 | $8,103.50 (85%) |
| 16060Radioactive 177Lutetium-DOTA treatment for inoperable or metastatic neuroendocrine tumours with high somatostatin receptor expression, approved by multidisciplinary team, including preparation, administration, aftercare, and specialist follow-up with… | $9,999.95 | $7,500.00 | $9,895.45 (85%) |